Michael H. Kroll MDProfessor of Medicine and Chief, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Michael Kroll is a hematologist and oncologist practicing in Houston, Texas. He is Professor of Medicine and Chief of the Section of Benign Hematology at the University of Texas MD Anderson Cancer Center (UTMDACC). His basic research background is in mechanisms of platelet-dependent thrombosis, and his academic clinical niche is benign hematology, hemostasis and thrombosis. His group’s research activities focus on mechanisms of cancer- and stem cell transplant–associated thrombotic microangiopathy, the prevention and treatment of venous thromboembolism in cancer patients, and mechanisms of cancer-induced venous thrombosis.
Dr. Kroll is intimately involved in fellowship training, co-directs UTMDACC’s Anticoagulant Stewardship Program, has published over 100 manuscripts in peer-reviewed journals, lectures world-wide over a dozen times per year, serves on 2 federal grant review committees, has received several awards for education and leadership, and has served The American Society of Hematology in various capacities.
Dr. Kroll received his medical degree from Cornell. He underwent residency training in internal medicine at Brown University and completed his fellowship in hematology/oncology at Harvard Medical School–Brigham & Women's Hospital.
Recent Contributions to PracticeUpdate:
- Thrombosis and Thrombocytopenia After ChAdOx1 nCoV-19 Vaccination
- Intermittent Pneumatic Compression in Addition to Standard Prophylaxis of Postoperative Venous Thromboembolism in Very High-Risk Patients
- Tissue Factor Pathway Inhibitor in Patients With Mild to Moderate Bleeding Tendency
- High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19
- Thrombotic Microangiopathy in Children With SARS-CoV-2
- Estimating the Risk Thresholds Used by Guidelines to Recommend Postpartum Thromboprophylaxis
- 2020 Top Stories in Benign Hematology: COVID-19–Associated Coagulopathy
- A Regimen With Caplacizumab, Immunosuppression and Plasma Exchange in Immune-Mediated TTP
- Real-World Evidence of Caplacizumab Use in the Management of Acute TTP